Fig. 5

Day 7 tumor antigen-specific CD8⁺ T cell immune response. MISIIR mice were treated with either IP M002 or PBS weekly for a total of 3 weeks. Mice were subsequently euthanized on day 7 or day 10 following the third injection. A representative day 7 flow cytometry gate demonstrating the number of tumor antigen-specific CD8⁺ T-cells for the Mesothelin tetramer in the omentum is illustrated for mice treated with M002 (a) and PBS (b). The day 7 tumor antigen-specific CD8⁺ T-cell immune response for the SV40-TAg and Mesothelin tetramer from the omentum, peritoneal fluid, draining lymph nodes, and spleen is demonstrated. The number of antigen-specific CD8⁺ T-cells was significantly larger to the SV40-TAg in the omentum (p = 0.04) and to Mesothelin in the omentum (p = 0.002) and peritoneal cavity (p = 0.02) (c)